Notices of duplicate publication
Notice of duplicate publication
It has been brought to our attention that the article published in December 2023 in the Journal of Obstetrics and Gynaecology, titled “Early prediction of the failure of methotrexate treatment by days 1–4 serum β-hCG change and 48-hour pre-treatment increment in β-hCG” [J Obstet Gynaecol. 2023;43(1):2183824. doi:10.1080/01443615.2023.2183824],¹ authored by Huijuan Zhou, has substantial overlap with another article in Advances in Clinical and Experimental Medicine reporting data from the same study, which was not cited or referenced.
The earlier article appeared in February 2023 in Advances in Clinical and Experimental Medicine, titled “Evaluation of pretreatment and early treatment changes in serum β-hCG with methotrexate” [Adv Clin Exp Med. 2023;32(2):195–202. doi:10.17219/acem/153043],² authored by Huijuan Zhou and Shuangdi Li.
The editors of the Journal of Obstetrics and Gynaecology have retracted the paper [doi:10.1080/01443615.2023.2183824],¹ while the editors of Advances in Clinical and Experimental Medicine, in accordance with the relevant COPE guidelines,³ are publishing this notice of duplicate publication. Since the article in Advances in Clinical and Experimental Medicine was published first, and there are no grounds for retraction from this journal, it will remain part of the scientific record.
It should be emphasized that this notice does not reflect any concerns regarding the scientific content of the article. However, duplicate (or redundant) publication – i.e., publishing the same research data in two or more journals – does not serve the interests of the medical or scientific community.
Prof. Donata Kurpas
Editor-in-Chief of Advances in Clinical and Experimental Medicine
Prof. Robert Śmigiel
Deputy Editor of Advances in Clinical and Experimental Medicine
Marek Misiak, MA
Managing Editor of Advances in Clinical and Experimental Medicine
REFERENCES
1. Zhou H. RETRACTED ARTICLE: Early prediction of the failure of methotrexate treatment by days 1–4 serum β-hCG change and 48-hour pre-treatment increment inβ-hCG. J Obstet Gynaecol. 2023;43(1):2183824. doi:10.1080/01443615.2023.2183824
2. Zhou H, Li S. Evaluation of pretreatment and early treatment changes in serum β-hCG with methotrexate. Adv Clin Exp Med. 2022;32(2):195–202. doi:10.17219/acem/153043
3. Committee on Publication Ethics (COPE). Redundant (duplicate) publication in a published article. Eastleigh, UK: Committee on Publication Ethics (COPE); 2025. https://publicationethics.org/guidance/flowchart/redundant-duplicate-publication-published-articleAccessed. September 15, 2025.